α-Amylase Inhibitors: A Review of Raw Material and Isolated Compounds from Plant Source

Paloma Michelle de Sales, Paula Monteiro de Souza, Luiz Alberto Simeoni, Pérola de Oliveira Magalhães, Dâmaris Silveira

Department of Pharmaceutical Sciences, School of Health Sciences, Campus Darcy Ribeiro, University of Brasília, Brasília, Brazil.

Received, October 25, 2011; Revised, January 8, 2012; Accepted, January 23, 2012; Published, January 25, 2012.

ABSTRACT - Inhibition of α-amylase, enzyme that plays a role in digestion of starch and glycogen, is considered a strategy for the treatment of disorders in carbohydrate uptake, such as diabetes and obesity, as well as, dental caries and periodontal diseases. Plants are an important source of chemical constituents with potential for inhibition of α-amylase and can be used as therapeutic or functional food sources. A review about crude extracts and isolated compounds from plant source that have been tested for α-amylase inhibitory activity has been done. The analysis of the results shows a variety of crude extracts that present α-amylase inhibitory activity and some of them had relevant activity when compared with controls used in the studies. Amongst the phyto-constituents that have been investigated, flavonoids are one of them that demonstrated the highest inhibitory activities with the potential of inhibition related to number of hydroxyl groups in the molecule of the compound. Several phyto-constituents and plant species as α-amylase inhibitors are being reported in this article. Majority of studies have focused on the anti-amylase phenolic compounds.

This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue’s contents page.

INTRODUCTION

Disorders of carbohydrate uptake may cause severe health problems such as diabetes (1), obesity (2), and oral diseases (3), all of which threaten an increasing worldwide population. Diabetes mellitus (DM) is a metabolic disorder resulting from deficiency in insulin secretion, insulin action, or both, promoting disturbance of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy, neuropathy, microangiopathy and increased risk of cardiovascular disease (1, 4, 5).

The therapeutic strategies for the treatment of type 2 diabetes include the reduction of the demand for insulin, stimulation of endogenous insulin secretion, enhancement of the action of insulin at the target tissues and the inhibition of degradation of oligo and disaccharides (6). The drugs commonly used in clinic to handle or control diabetes are insulin, sulfonylureas, biguanide, glucosidase inhibitors, aldose reductase inhibitor, thiazolidinediones, carbamoylmethyl benzoic acid, insulin-like growth factor. The effect of these drugs is aimed to lower the level of blood glucose (4, 7, 8). One therapeutic approach for treating type 2 diabetes mellitus is to decrease the post-prandial glucose levels. This could be done by retarding the absorption of glucose through the inhibition of the carbohydrates-hydrolysing enzymes, α-glucosidase and α-amylase, present in the small intestinal brush border that are responsible for the breakdown of oligosaccharides and disaccharides into monosaccharides suitable for absorption (1, 7, 9, 10). Inhibitors of these enzymes, like acarbose, delay carbohydrate digestion and prolong overall carbohydrate digestion time, causing a reduction in the rate of glucose absorption and consequently blunting the post-prandial plasma glucose rise (1, 4).

Dental caries and periodontal diseases are the most prevalent oral infectious diseases that cause significantly impact a person’s overall health, having considerable economic impact, if not adequate treated (3, 11).

Corresponding Author: Pérola de Oliveira Magalhães, Universidade de Brasília/UnB Faculdade de Ciências da Saúde, Departamento de Farmácia, Campus Universitário Darcy Ribeiro, Asa Norte CEP 70900-910, Brasília, Distrito Federal, Brasil. E-mail: perolamagalhaes@unb.br
Take part in etiopathology of dental caries, the most abundant enzyme in human saliva, α-amylase salivary, possess at least three distinct biological functions in the oral cavity (12). First, its hydrolytic activity is responsible for the initial break down of starch to oligosaccharides. Second, several lines of evidence indicate that salivary α-amylase bound to tooth enamel or hydroxyapatite may play a role in dental plaque formation. Third, α-amylase in solution binds with high affinity to viridans oral streptococci and bacteria-bound α-amylase is capable of hydrolyzing starch to glucose, which can be used as a food source and then further metabolized to lactic acid. Localized acid production by bacteria can lead to the dissolution of tooth enamel, a critical step in dental caries progression (12, 13). Because of its central role in the oral cavity, α-amylase salivary has been exploited as a target for the structure-assisted design of compounds that might prevent unwanted dental plaque formation and the subsequent process of dental caries formation and progression. Ethnopharmacological approach and bioassay-guided isolation have provided a lead in identifying potential α-amylase inhibitors from plant sources. Currently, methods to determine the levels of α-amylase inhibitor are based on the measurement of α-amylase activity resulting by the different iodine staining power in the presence or absence of an inhibitor during the action of the enzyme on soluble starch or by using an alkaline reactive whose brown reduction products are determined photometrically as reported by Bernfeld (14, 15). This review highlights on the plants and their active constituents so far reported to have α-amylase inhibitory activity.

CHARACTERISTICS OF α-AMYLASE

The α-amylase (α -1,4-glucan-4-glucanohydrolases; E.C. 3.2.1.1) is one of the major secretory products of the pancreas (about 5–6%) (16) and salivary glands, playing a role in digestion of starch and glycogen and can be found in microorganisms, plants and higher organisms (17). The α-amylase constitute a family of endo-amylases that catalyse the initial hydrolysis of starch into shorter oligosaccharides through the cleavage of α-D-(1-4) glycosidic bonds (17-20). Neither terminal glucose residues nor α-1,6-linkages can be cleaved by α-amylase (16). The end products of α-amylase action are oligosaccharides with varying length with an α-configuration and α-limit dextrans (21), which constitute a mixture of maltose, maltooltriose, and branched oligosaccharides of 6–8 glucose units that contain both α-1,4 and α-1,6 linkages (16). Others amylolytic enzymes participate in the process of starch breakdown, but the contribution of α-amylase is a prerequisite for the initiation of this process (19).

The human α-amylase is classical calcium-containing enzyme composed of 512 amino acids in a single oligosaccharide chain with a molecular weight of 57.6 kDa (16). There are five α-amylase genes clustered in chromosome 1, at location 1q21, in humans. Three of them code for salivary R-amylase, AMY1A, AMY1B, and AMY1C, and the other two genes AMY2A and AMY2B are expressed in the pancreas (22, 23). Human salivary and pancreatic α-amylases share a high degree of amino acid sequence similarity with 97% identical residues overall and 92% in the catalytic domains (12, 18).

The amylase presents a three-dimensional structure capable of binding to substrate and, by the action of highly specific catalytic groups, promote the breakage of the glycoside links (20). The protein contains 3 domains: A, B, and C. Domain A, which has a (β/α)8 barrel fold, constitutes the catalytic core domain. It contains about 280–300 residues. The catalytic triad (Asp, Asp, Glu) is present in domain A (24, 25). The B domain is inserted between A and C domains and is attached to the A domain by disulphide bond. The C domain presents a β sheet structure linked to the A domain by a simple polypeptide chain and seems to be an independent domain with unknown function. The active site (substrate-binding) of the α-amylase is situated in a long cleft located between the carboxyl end of both A and B domains. The calcium (Ca2+) is situated between A and B domains and may act in stabilizing the three-dimensional structure and as an allosteric activator. The substrate-binding site contains 5 subsites (-3 -2 -1 +1 +2) (26).

α-Amylase catalyze the hydrolysis of starch via a double displacement mechanism involving the formation and hydrolysis of a covalent β-glycosyl enzyme intermediate by using active site carboxylic acids for it (27). The residues, in particular, Asp197, Glu233, and Asp309 were described to function as catalytic residues (26, 27). Probably, Asp197 acts as nucleophile that attacks the substrate at the sugar anomeric center, forming a covalently bound reaction intermediate. In this step, the reducing end of the substrate is cleaved off the sugar skeleton. In a second step a water molecule attacks the anomeric center to
break the covalent bond between Asp\(^{197}\) and the substrate, attaching a hydroxyl group to the anomic center. In both steps Glu\(^{232}\) and Asp\(^{300}\) either individually or collectively act as acid/base catalysts. As a consequence, the active site of human \(\alpha\)-amylase consists of several major binding subsites identified through kinetic studies (26). The same studies show that the “-1”, “-2”, and “-3” pocket is the core of the catalytic reaction (26).

INHIBITORS OF \(\alpha\)-AMYLASE FROM PLANTS

The potential role of the medicinal plants as inhibitors of \(\alpha\)-amylase has been reviewed by several authors. A variety of plants has been reported to show \(\alpha\)-amylase inhibitory activity and so may be relevant to the treatment of type 2 diabetes. About 800 plant species have been reported to possess antidiabetic properties. A wide range of plant-derived principles belonging to compounds, mainly alkaloids, glycosides, galactomannan gum, polysaccharides, hypoglycans, peptidoglycans, guanidine, steroids, glycopeptides and terpenoids, have demonstrated bioactivity against hyperglycaemia (28). A list of plants reported to have significant \(\alpha\)-amylase inhibitory activity is shown in Table 1.

*Syzygium cumini* L. (syn: *Eugenia jambolana* Lam.) and *Psidium guajava* L. are widely used traditional system of medicine to treat diabetes in India (29). The aqueous extracts from *S. cumini* seeds and *P. guajava* leaves both showed a dose-dependent inhibitory effect on \(\alpha\)-amylase activity (29). The extract from seeds of *S. cumini* also significantly decreased the levels of blood glucose on diabetic rats (28, 30). Conforti and cols. (2005) (31) demonstrated that methanol, ethyl acetate and hexane extracts from two varieties of *Amaranthus caudatus* L. seeds (Oscar blanco and Victor red. Oil) showed \(\alpha\)-amylase inhibitory activity (above 80% inhibition rate) at 0.25-1mg/mL.

The buffered extracts of several plant species namely *Balanites aegyptiaca* L., *Camellia sinensis* L. Del., *Galega officinalis* L., *Holarrhena floribunda* (Don) Durand & Schinz, *Khaya senegalensis* (Desr.) A. Juss., *Melissa officinalis* L., *Mitragyna inermis* (Willd.) O. Ktze., *Rosmarinus officinalis* L., *Securidaca longipedunculata* Fresen., *Tamarindus indica* L., *Taraxacum officinale* Web. ex Wigg., and *Vaccinium myrtillus* L. were screened for \(\alpha\)-amylase activity and showed remarkable inhibitory activity (above 45% inhibition rate at 0.2g/mL) (6). Methanol extracts of 41 plants, used in traditional Mongolian medicine have been tested for \(\alpha\)-amylase inhibitory properties and significant inhibition of the enzyme was shown by *Rhodiola rosea* L., *Ribes pulchelum* Turcz, and *Vaccinium uliginosum* L.; extracts from *Geranium pretense* L., *Leontopodium ochroleucum* Beauv., *Paecinia anomala* L., and *Pentaphylloides frutisca* L. Schwarz showed \(\alpha\)-amylase inhibitory activity greater than 30% (32). Loizzo and cols (2008) screened the methanol, hexane and chloroform extracts from nine Lebanon traditional medicinal plants recommended in Lebanon for diabetes and found that the methanol extracts of *Salvia acetabulosa* L. and *Marrubium radiatun* Dev ex Benth exerted the highest inhibitory activity against \(\alpha\)-amylase (33).

Ayurveda, the traditional Indian herbal medicinal system practiced for over thousands of years have reports of antidiabetic plants with no apparent known side effects (34, 35). Chloroform extracts of six plants namely *Azadirachta indica* A. Juss, *S. cumini*, *Ocimum tenuflorum* L., *Murraya koenigii* (L.) Spreng., and *Linum usitatissimum* L., traditionally used in Ayurveda along with *Bougainvillea spectabilis* Wild. used as a hypoglycemic plant in West Indies, and some parts of Asia were screened for inhibitory activity on \(\alpha\)-amylase (34). A significant inhibition was observed with extracts of *O. tenuflorum* (34). Other six Indian medicinal plants were tested for their effect on \(\alpha\)-amylase activity. Among them, *Mangifera indica* L., *Embelta ribes* Burm., *Phyllanthus maderaspatensis* Linn. and *Punica granatum* L. showed interesting \(\alpha\)-amylase inhibitory activity (36).

The proteinaceous inhibitor of \(\alpha\)-amylase (\(\alpha\)AI), which inhibits animal salivary and pancreatic \(\alpha\)-amylase, has been identified and isolated from various plant species (37). Amongst this plants, seeds of *Phaseolus vulgaris* L. contain proteinaceous inhibitors of the \(\alpha\)-amylase and the isofrom inhibitor \(\alpha\)AI-1 have been isolated and characterized (38, 39). The common bean \(\alpha\)AI-1 has been reported to have relatively great potential as an extensive anti-obesity and anti-diabetes remedy (37).

PHYTOCONSTITUENTS WITH \(\alpha\)-AMYLASE INHIBITORY ACTIVITY

A wide array of plant has derived numerous chemical compounds that have demonstrated
activity consistent with their possible use in the treatment of diabetes. Research on new bioactive compounds from medicinal plants has led to isolation and structure elucidation of a number of exciting new pharmacophores. A list of phytoconstituents having significant α-amylase inhibitory activity is provided in Table 2.

Oligosaccharide inhibitors of the trestatin family that contain the acarviosine moiety (e.g., acarbose I), proteinaceous inhibitors isolated from microbial sources and plant tissues (40) and molecules present in plants comprise the natural inhibitors of α-amylase (41). Acarbose I, a well-known drug widely used for clinical treatment of diabetes mellitus, is a pseudotetrasaccharide, produced by Actinoplanes sp. fermentation, consisting of a polyhydroxylated aminocyclohexene derivative (valienamine) linked via its nitrogen atom to a 6-deoxyglucose, which is itself α-1,4-linked to a maltose moiety. It is a competitive inhibitor of α-amylase and the mechanism of inhibition seems to be due to the unsaturated cyclohexene ring and the glycosidic nitrogen linkage that mimics the transition state for the cleavage enzymatic of glycosidic linkages (42, 43).

In the structural study of the human pancreatic α-amylase/acarbose complex, acarbose inhibitor was described to bind subsites “-3” through “+2” (26). In acarbose the valienamine moiety is found in binding subsite -1 and its strong inhibition is believed to result from enhanced binding of this moiety with the side chain of Asp$^{197}$, Glu$^{233}$, and Asp$^{300}$ residues in the binding site (substitution of these residues leading to a considerable drop in catalytic activity) (26).

Acarbose I is metabolised by small and large intestinal carbohydrases to give acarviosine-glucose and glucose (43). The main adverse effects observed with acarbose are gastrointestinal, including abdominal discomfort, flatulence, meteorism and diarrhea (8, 43, 44). These adverse effects might be caused by the increase of degradation products in the intestine resulting in the abnormal bacterial fermentation of undigested carbohydrates (43, 44). Indeed, these main side effects are common to α-amylase inhibitors. Specifically, bloating, abdominal discomfort, diarrhea and flatulence occur in about 20% of patients (45). Frequently such effects lead to therapy discontinuation (7). α-Glucosidase inhibitors are contraindicated in patients with irritable bowel syndrome or severe kidney or liver dysfunction. Inflammatory bowel disease is a relative contraindication (4). There are also reports of an increased occurrence of renal tumors occurrence and serious hepatic injury and acute hepatitis (46).

Studies with healthy and type 2 diabetes subjects showed that natural α-amylases inhibitors isolated from wheat (47) and white bean (48) significantly reduced the peak of postprandial glucose. Inhibitory profiles were investigated in green, oolong and black teas and the results suggested that catechins may be responsible for its activity in human salivary α-amylase (49).
Therefore, the present article reviews and shows in Table 1 a list of compounds with human α-amylase inhibitory capacity.

Phenolic compounds are a large group of structurally diverse naturally occurring compounds that possess at least a phenolic moiety in their structures. Most of these compounds possess various degrees of antioxidant or free radical scavenging properties as well as medicinal properties and have long been used as drugs.

Flavonoids are abundant class of natural phenolic compounds with several biological activities. They share a common structural skeleton consisting of two aromatic rings (A and B) linked through three carbons attached to the A-ring, forming an oxygenated heterocycle (ring C) and are divided in groups (Figure 1).

**Figure 1.** Flavonoids basic skeletons
Lo Piparo et al. (2008) investigated the interactions between flavonoids and human α-amylase in order to understand the molecular requirement for enzyme inhibition. They showed that the potency of inhibition is correlated with the number of hydroxyl groups on the B ring of the flavonoid skeleton. The interaction occurs with the formation of hydrogen bonds between the hydroxyl groups in position R6 or R7 of the ring A and position R4’ or R5’ of the ring B of the polyphenol ligands and the catalytic residues of the binding site and formation of a conjugated π-system that stabilizes the interaction with the active site (41). These results are in general agreement with the mechanism of action proposed for acarbose (50).

Tannins are another heterogeneous polyphenol group widely distributed in the plant kingdom that are often present in unripe fruits, but can disappear during ripening. They have a relatively high molecular weight and can be classified into two major classes: hydrolysable tannins and condensed tannins. Hydrolysable tannins are subdivided into gallotannins, derived from gallic acid \[ \text{H}_2\text{C} = \text{O} \] units linked to a sugar moiety), while condensed tannins are complex polymers, where the building blocks are usually catechins and flavonoids (51).

Several polyphenolic compounds presenting α-amylase inhibitory activity are shown at Figures 2, 3, and 4. Tannins could cause several effects on the biological system because they are potential metal ion chelators and protein precipitation agents forming insoluble complexes with proteins, as well as biological oxidants (52). Tannic acid and tannin-rich nonalcoholic components of red wine have been shown to reduce serum glucose levels after starch-rich meals in a study of patients with non-insulin dependent diabetes mellitus (53). As the mechanism involved in this anti-hyperglycemic effect is unknown, it is possible that tannins can inhibit α-amylase activity in situ. The ability to strongly bind to proteins forming insoluble and indigestible complex is the basis of their extensive use in the leather industry (tanning process), and for the treatment of diarrhea, bleeding, skin injuries (54) and probably it is the action mechanism to cause inhibition of the enzyme α-amylase.

Terpenoids are compounds that comprise various structures commonly found in nature with a several function in plants and animals. They usually arise from head-to-tail joining of isoprene units and a combination of two or more isoprene units divide the terpenoids in monoterpenes (C_{10}), sesquiterpenes (C_{15}), diterpenes (C_{20}), sesterterpenes (C_{23}), triterpenes (C_{30}) and tetraterpenes (C_{40}) (55).

Triterpenoids are a large and structurally diverse group of natural products derived from squalene [3] or related acyclic 30-carbon precursors (56) with several potential uses in medicine. Some triterpenoids with well-characterized biological activities include sterols, steroids, and saponins (57).

A range of real and potential usable biological effects are being studied for triterpenoids. Anti-inflammatory, analgesic, antimicrobial, antymycotic, antiviral, antiplasmodial, antiulcerogenic, anticarogenic, immunomodulatory, vascular protective, antiobese, anticancer and tonic effects are ones the use related uses for this class of compound (58, 59). Hepato and cardioprotective activity were also related for triterpenoids (59-61). Triterpenoids represent a promising and expanding source for biologically active natural compounds whose potential for research and development of new substances with pharmacologic activity. However, despite the fact that triterpenoids are widely distribute in plants, inhibitory α-amylase activity was related only for oleanane, ursane and lupane types and the mechanism by which this activity occur still unknown. Some terpenes presenting inhibitory activity on α-amylase are shown at Figure 5.

CONCLUSION

α-Amylase, a salivary or pancreatic enzyme plays an important role in early breakdown of complex carbohydrates into simple molecules. Modulation of α-amylase activity affects the utilization of carbohydrates as an energy source and stronger is this modulation; more significant is the reduction is the breakdown of complex carbohydrates. Majority of studies have focused on the antiamylase phenolic compounds.

The action mechanism proposed for inhibitory capacity of flavonoids correlated the
potency of inhibition of these compounds with the number of hydroxyl groups on the B ring of the flavonoid skeleton with the formation of hydrogen bonds between the hydroxyl groups of the polyphenol ligands and the catalytic residues of the binding site of the enzyme. The high inhibitory capacity is observed in flavonols and flavones groups.

The main inhibitory effects of the tannins is related with its the ability to strongly bind to carbohydrates and proteins. However, Kandra et al. (2004) suggested that the interaction between tannins, such galloylated quinic acid, and human α-amylase is also correlated with free OH groups in the tannin, that are able to participate in hydrogen bonding (51). However, in this review is possible to note that tannins are not always an effective inhibitor of α-amylase.

The significant differences in inhibitory activity for α-amylase were shown in luteolin-7-O-glucoside [9b] from different studies. This compound showed 100% of inhibition in one study and 50% of inhibition in another. The same methodology was carried out to evaluate this activity in both studies, however the concentration of tested compound and incubation time of enzyme were different for both (6, 62).

Inhibitory activities ranging from 100% to 50% were also observed for fisetin [4c] and luteolin [9a]. The analyzed studies showed differences in the concentration of tested compound, incubation time of enzyme and substrate solution used (6, 41, 62), and the impact that changes can be noted in the obtained results.

Differences in percentage of inhibition were also observed for rosmarinic acid [28] and daidzein [15a]. Inhibitions of 85% and 50% for rosmarinic acid and 23% and 55% for daidzein were shown in the assays using starch and p-nitrophenyl-α-D- maltopentaoside (PNPG) as a substrate, respectively (6, 41, 62, 63).

The comparison of inhibitory activity to α-amylase showing in the studies allows to observe significant differences in percentage of inhibition for the same compound. This is due a several number of valuable assay methods for available the amylase activity. Between them, two types of assays are largely used to determine the action of α-amylase. One is based on increase in reducing power of the substrate by the dinitrosalicylic acid (DNS) reagent (64), whereas the other is based on the change of the iodine- staining properties of the substrate (65). Thus, some modifications in this assays reported by researchers could express different results for α-amylase inhibitory activity.

As the intake of phenolic compounds is associated with many beneficial effects, it is also necessary to consider the dose for humans, because it is possible to reduce α-amylase activity by consuming food or medicinal herbs rich in polyphenols with strong α-amylase activity, if it takes in consideration that this source of polyphenols possess different kinds of this compounds in variable concentration. Therefore, more available evidences are necessary about the safety of using natural α-amylase inhibitor.

Also, there is need for novel agents, therapeutic strategies or designing functional foods that could act on the physiological regulation of sugar uptake, blood sugar levels, and prevention of oral diseases.

For the future, a standardized protocol to search potential inhibitors maybe should be designed in order to minimize the differences among obtained results.

REFERENCES

1. Laer FA, Lucassen PLBJ, Akkermans RP, Lisdonk EH, Rutten GEHM, Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane Review). The Cochrane Library, 2008.
2. Yanovski SZ, Yanovski JA. Drug Therapy: Obesity. N. Engl. J. Med., 2002; 346: 5991-602.
3. Touger-Decker R, Loveren CV. Sugars and dental caries. Am. J. Clin. Nutr., 2003; 78: 88S–92S.
4. Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes Mellitus. Can. Med. Assoc. J., 2005; 172: 213-226.
5. Aguiar LGK, Villela NR, Bouskela EA. Microcirculação no Diabetes: Implicações nas Complicações Crônicas e Tratamento da Doença. Arq Bras Endocrinol Metab 2007; 51: 204-211.
6. Funke I, Melzing MF. Traditionally used plants in diabetes therapy - phytotherapeutics as inhibitors of α-amylase activity. Rev Bras Farmacogn, 2006; 16: 1-5.
7. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA, 2002; 287: 360-372.
8. Chakrabarti R, Rajagopalan R. Diabetes and insulin resistance associated disorders: Disease and the therapy. Current Sci, 2002; 83: 1533-1538.
9. Goke B, Herrmann-Rinke C. The evolving role of α-glucosidase inhibitors. Diabetes/Metab Res., 1998; 14: S31-S38.
10. Lebowitz HE. alpha-glucosidase inhibitors as agents in the treatment of diabetes Diabetes Rev, 1998; 6: 132-145.
11. Rudney JD. Saliva and dental plaque. Adv. Dental Res., 2000; 14: 29-39.
12. Ramasubbu N, Paloth V, Luo Y, Brayer GD, Levine MJ. Structure of human salivary alpha-amylase at 1.6 A resolution: implications for its
role in the oral cavity. Acta Crystalloegl., Sect. D.: Biol. Crystallogr., 1996; 52: 435-446.

13. Scannapieco FA, Torres G, Levine MJ. Salivary α-amylase: role in dental plaque and caries formation. Crit. Rev. Oral Biol. Med., 1993; 4: 301-307.

14. Bernfeld P. Amylases α and β. In Methods in Enzymology, Colowick, S. P.; Kaplan, N. O., Eds. Academic Press, Inc: San Diego, 1955; Vol. 1, pp 149-158.

15. Mosca M, Bonigia C, Carrat G, Giannaroli S, Nera V, Sanzini E. Determination of [alpha]-amylase inhibitor activity of phaseolamin from kidney bean (Phaseolus vulgaris) in dietary supplements by HPAEC-PAD. Anal Chim Acta, 2008; 617: 192-195.

16. Whitcomb DC, Lowe ME. Human Pancreatic Digestive Enzymes. Digestive Diseases Sciences, 2008; 617: 192-195.

17. Kandra L. Digestive Enzymes. Digestive Diseases Sciences. Whitcomb DC, Lowe ME. Human Pancreatic Digestive Enzymes, 2008; 617: 192-195.

18. Brayer GD, Luo Y, Withers SG. The structure of human pancreatic α-amylase at 1.8 Å resolution and comparisons with related enzymes. Protein Sci, 1995; 4: 1730-1742.

19. Tangphatsornruang S, Naconsie M, Thammarongtham C, Narangajavana J. Isolation and characterization of an α-amylase gene in cassava (Manihot esculenta). Plant Physiol., 2005; 43: 821-827.

20. Iulek J, Franco DL, Silva M, Slivinski CT, Bloch Jr C, Rigden DJ, Sâm FG. Purification, biochemical characterisation and partial primary structure of a new α-amylase inhibitor from Secale cereale (rye). Int. J. Biochem. Cell Biol, 2000; 32: 1195-1204.

21. Maarel MJEC, Veen B, Uitdehaag JCM, Leemhuis H, Dijkhuizen L. Properties and applications of starch-converting enzymes of the α-amylase family. J. Biotechnol., 2002; 94: 137-155.

22. Groot PC, Bleeker MJ, Pronk JC, Arwert F, Mager WH, Planta RJ, Eriksson AW, Frants RR. Human pancreatic amylase is encoded by two different genes. Nucleic Acids Res, 1988; 16: 4724.

23. Gumucio DL, Wiebauer K, Caldwell RM, Samuelsen LC, Meisler MH. Concerted evolution of human amylase genes. Mol Cell Biol, 1988; 8: 1197-1205.

24. Van der Maarel MJEC, Van der Veen B, Uitdehaag JC, Leemhuis H, Dijkhuizen L. Properties and applications of starch-converting enzymes of the α-amylase family. J. Biotechnol., 2002; 94: 137-155.

25. Janecek S, Svensson B, Henrikss B. Domain evolution in the α-amylase family. J. Mol. Evol., 1997; 45: 322-331.

26. Brayer GD, Sidhu G, Maurus R, Rydberg EH, Braun C, Wang Y, Nguyen NT, Overall CM, Withers SG. Subsite mapping of the human pancreatic alpha-amylase active site through structural, kinetic and mutagenesis techniques. Biochemistry-US, 2000; 39: 4778-4791.

27. Rydberg EH, Li C, Maurus R, Overall CM, Brayer GD, Withers SG. Mechanistic analyses of catalysis in human pancreatic α-amylase: Detailed kinetic and structural studies of mutants of three conserved carboxylic acids. Biochemistry, 2002; 41: 4492-4502.

28. Mentreddy SR. Medicinal plant species with potential antidiabetic properties. J. Sci. Food Agric., 2007; 87: 743-750.

29. Karthic K, Kirthiram KS, Sadasivam S, Thayumanavan B. Identification of α-amylase inhibitors from Syzygium cumini Linn seeds. Indian J. Exp. Biol., 2008; 46: 677-680.

30. Kumar A, Ilavarasan R, Jayachandran T, Deecaraman M, Aravindan P, Padmanabhan N, Krishan M. Anti-diabetic activity of Syzygium cumini and it’s isolated compound against streptozotocin-induced diabetic rats. J. Med. Plants Res., 2008; 2: 246-249.

31. Conforti F, Statti G, Loizzo MR, Sacchetti G, Poli F, Menichini F. In Vitro Antioxidant Effect and Inhibition of α-Amylase of Two Varieties of Amaranthus caudatus Seeds. Biol Pharm Bull, 2005; 28: 1098-1102.

32. Kobayashi K, Baba E, Fushiya S, Takano F, Batkhhuu J, Dash T, Sanchir F, Yoshizaki F. Screening of Mongolian Plants for Influence on Amylase Activity in Mouse Plasma and Gastrointestinal Tube. Biol. Pharm. Bull., 2003; 26: 1045-1048.

33. Loizzo MR, Saab AM, Tundis R, Menichini F, Bonesi M, Piccolo V, Statti GA, Cindio B, Houghton PJ. In vitro inhibitory activities of plants used in Lebanon traditional medicine against angiotensin converting enzyme (ACE) and digestive enzymes related to diabetes. J. Ethnopharm., 2008; 119: 109-116.

34. Bhat M, Zinjarde SS, Bhargava SY, Kumar AR, Joshi BN. Antidiabetic Indian plants: a good source of potent amylase inhibitors. Evid. Based Complement. Alternat. Med., 2011; 2011: 6.

35. Bhutani KK, Gohil VM. Natural products drug discovery research in India: status and appraisal. Indian J Exp Biol, 2010; 48: 199-207.

36. Prashanth D, Padmaja R, Samuilla DS. Effect of certain plant extracts on [alpha]-amylase activity. Fitoterapia, 2001; 72: 179-181.

37. Wang HH, Chen CL, Jeng TL, Sung JM. Comparisons of [alpha]-amylase inhibitors from seeds of common bean mutants extracted through three phase partitioning. Food Chem., 2011; 128: 1066-1071.

38. Yamada T, Hattori K, Ishimoto M. Purification and characterization of two [alpha]-amylase inhibitors from seeds of tepary bean (Phaseolus acutifolius A. Gray). Phytochemistry, 2001; 58: 59-66.

39. Le Berre-Anton V, Bomard-Gilles C, Payan F, Rougé P. Characterization and functional
properties of the [alpha]-amylase inhibitor ([alpha]-AI) from kidney bean (Phaseolus vulgaris) seeds. Biochim. Biophys. Acta, 1997; 1343: 31-40.

40. Svensson B, Fukuda K, Nielsen PK, Bonsager BC. Proteinaceous a-amylase inhibitors. Biochim Biophys Acta, 2004; 1696: 145-156.

41. Lo Piparo E, Scheib H, Frei N, Williamson G, Grigorov M, Choi CJ. Flavonoids for Controlling Starch Digestion: Structural Requirements for Inhibiting Human a-Amylase. J. Med. Chem., 2008; 51: 3555-3561.

42. Yoon SH, Robyt JF. Study of the inhibition of four alpha amylases by acarbose and its 4IV-α-maltohexaosyl and 4IV-α-maltododecaosyl analogues. Carbohydr. Res., 2003; 338: 1969-1980.

43. Gyémánt G, Kandra L, Nagy V, Somsák L. Inhibition of human salivary α-amylase by glucopyranosylidene-spiro-thiohydantoin. Biochem Biophys Res Commun, 2003; 312: 334-339.

44. Kwon YI, Apostolidis E, Shetty K. In vitro studies of eggplant (Solanum melongena) phenolics as inhibitors of key enzymes relevant for type 2 diabetes and hypertension. Bioresearch Technol, 2008, 99: 2981-2988.

45. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet, 2002; 359: 2072-2077.

46. Murai A, Iwanaka K, Takada M, Ogawa K, Usui T, Okamura J. Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice. J. Agric. Food Chem., 2002; 94: 387-394.

47. Lankisch M, Layer P, Rizza RA, DiMagno EP. Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) from kidney bean (Phaseolus vulgaris) seeds. Biochim Biophys Acta, 1997; 1343: 31-40.

48. Koh LW, Wong LL, Loo YY, Kasapis S, Huang D. Evaluation of Different Teas against Starch Digestibility by Mammalian Glycosidases. J Agric. Food Chem., 2010; 58: 148-154.

49. Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes, 2005; 54: 1615-1625.

50. Kandra L, Gyémánt G, Zajácz A, Battag G. Inhibitory effects of tannin on human salivary α-amylase. Biochem Biophys Res Commun, 2004; 319: 1265-1271.

51. Quideau S, Jourdes M, Saucier C, Glories Y, Pardon P, Baudry C. DNA topoisomerase inhibitor acutissimin A and other flavano-ellagitannins in red wine. Angew Chem. Int. Ed., 2003; 42: 6012-6014.

52. Gin H, Rigalleau V, Caubet O, Aubertin J. Effects of red wine, tannic acid, or ethanol on glucose tolerance in non-insulin dependent diabetic patients and on starch digestibility in vitro. Metabolism, 1999; 48: 1179-1183.

53. Zajácz A, Gyémény G, Vittorib N, Kandraa L. Alepp tannin: structural analysis and salivary amylase inhibition. Carbohydr. Res., 2007; 342: 717-723.

54. McGarvey DJ, Croteau R. Terpenoid metabolism. Plant Cell, 1995; 7: 1015-1026.

55. Connolly JD, Hill RA. Triterpenoids. Nat Prod Rep, 1999; 16: 221-240.

56. Xu R, Fazio GC, Matsuda SPT. On the origins of triterpenoid skeletal diversity. Phytochemistry, 2004; 65: 261-291.

57. Melo CL, Queiroz MG, Arruda Filho ACV, Rodrigues AM, Sousa DF, Almeida JG, Pessoa ODL, Silveira ER, Menezes DB, Melo TS, Santos FA, Rao VS. Betuline acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. J. Agric. Food Chem., 2009; 57: 8776-8781.

58. Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep, 2006; 23: 394-411.

59. Tang X, Gao J, Chen J, Fang F, Wang Y, Dou H, Xu Q, Qian Z. Inhibition of ursolic acid on calcium-induced mitochondrial permeability transition and release of two proapoptotic proteins. Biochem. Biophys. Res. Comm, 2005; 11: 320-324.

60. Jeong HG, Kim HG, Hwang YP. Involvement of cytokines in the hepatic expression of metallothionein by ursolic acid Toxicol Lett, 2005; 155: 369-376.

61. Kim JS, Kwon CS, Son KH. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid Biochem. Biotechnol. Biochem., 2000; 64: 2458-2461.

62. McCue PP, Shetty K. Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in vitro. Asia Pac. J. Clin. Nut., 2004; 13: 101-106.

63. Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal. Chem., 1959; 31: 426-428.

64. Fuwa H. A New method for microdetermination of amylose activity by the use of amylose as the substrate. J. Biochem, 1954; 41: 583-603.

65. Subramanian R, Asmawi MZ, Sadikun A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochim. Pol., 2008; 55: 391-398.

66. Shirosaki M, Koyama T, Yazawa K. Antihyperglycemic activity of kiwifruit leaf (Actinidia deliciosa) in mice. Biosc. Biotechnol. Biochem., 2008; 72: 1099-1102.
68. Al-Dabbas MM, Kitahara K, Suganuma T, Hashimoto F, Tadera K. Antioxidant and α-Amylase Inhibitory Compounds from Aerial Parts of *Varthemia iphionoides* Boiss. Biosci. Biotech. Biochem., 2006; 70: 2178-2184.

69. Silva Pinto M, Kwon YI, Apostolidis E, Lajolo FM, Genovese MI, Shetty K. Potential of Ginkgo biloba L. leaves in the management of hyperglycemia and hypertension using in vitro models. Bioreas. Technol., 2009; 100: 6599-6609.

70. Ali H, Houghton PJ, Soumyanath A. α-amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to *Phyllanthus amarus*. J. Ethnopharmacol., 2006; 107: 449-455.

71. Giri AP, Kachole MS. Amylase inhibitors of pigeonpea (*Cajanus cajan*) seeds. Phytochemistry, 1998; 47: 197-202.

72. Guzman-Partida A, Jatomea-Fino O, Robles-Burgueño M, Ortega-Nieblas M, Vazquez-Moreno L. Characterization of [alpha]-amylase inhibitor from Palo Fierro seeds. Plant Physiology and Biochemistry, 2007; 45: 711-715.

73. Hansawasdi C, Kawabata J, Kasai T. α-amylase Inhibitors from Roselle (*Hibiscus sabdariffa* Linn.) Tea. Biosci. Biotechnol. Biochem., 2000; 64: 1041-1043.

74. Thalapaneni NR, Chidambaram KA, Ellappan T, Sahapathi ML, Mandal SC. Inhibition of Carbohydrate Digestive Enzymes by Talinum portulacifolium (*Forssk*) Leaf Extract. J. Complement. Integr. Med., 2008; 5: 11.

75. Bhandari MR, Jong-Anurakkun N, Gao Hong JK. α-Glucosidase and α-amylase inhibitory activities of Nepalese medicinal herb Pakhanbhed (*Bergenia ciliata*, Haw.). Food Chem, 2008; 106: 247-252.

76. Mohamed GA. Alliuocide G, a new flavonoid with potent α-amylase inhibitory activity from *Allium cepa* L. Arkivoc, 2008; 9: 202-209.

77. Kawaguchi M, Tanabe H, Nagamine K. Isolation and characterization of a novel flavonoid possessing a 4,2'-glycosidic linkage from green mature acerola (*Malpighia emarginata* DC.) fruit. Biosc. Biotechnol. Biochem., 2007; 71: 1130-1135.

78. Jullian C, Miranda S, Zapata-Torres G, Mendiza’balc F, Olea-Azarb C. Studies of inclusion complexes of natural and modified cyclodextrin with (+)catechin by NMR and molecular modeling. Bioorg. Med. Chem., 2007; 15: 3217-3224.

79. Fred-Jaiyesimi A, Kio A, Richard W. α-Amylase inhibitory effect of 3β-olean-12-en-3-yl (9Z)-hexadec-9-enoate isolated from *Spondias mombin* leaf. Food Chem, 2009; 116: 285-288.

80. McDougall GJ, Shpiro F, Dobson P, Smith P, Blake A, Stewart D. Different polyphenolic components of soft fruits inhibit α-amylase and α-glucosidase. J. Agric. Food Chem., 2005; 53: 2760-2766.

81. Ani V, Akhilender Naidu K. Antihyperglycemic activity of polyphenolic components of black/bitter cumin *Centratherum anthelminticum* (L.) Kuntze seeds. Eu Food Res Technol, 2008; 226: 897-903.
Table 1. Plants with α-amylase inhibitory activity

| Plant             | Parts used       | Type of extract | Activity (% inhibition) (concentration) | Control                                      | References |
|-------------------|------------------|-----------------|----------------------------------------|----------------------------------------------|------------|
| **Acanthaceae**   |                  |                 |                                        |                                              |            |
| *Andrographis paniculata* Nees | Leaf and aerial parts | Ethanol         | 52.5 (50.9mg/mL) 54.8 (11.3mg/mL) | Acarbose with 50.1% of maxim inhibition at 10mg/mL | (66)       |
| **Actinidiaceae** |                  |                 |                                        |                                              |            |
| *Actinidia deliciosa* (A.Chev.) C.F.Liang & A.R.Ferguson | Leaf | Methanol 90% | 50 (0.0429mg/mL) | Acarbose with inhibition higher than 75% at 0.0466mg/mL | (67)       |
| **Amaranthaceae** |                  |                 |                                        |                                              |            |
| *Amaranthus caudatus* var. Oscar blanco | Seed | Methanol | 94.71 (1mg/mL) | Non-treated enzyme                                    | (31)       |
| *Amaranthus caudatus* var. Victor red | Seed | Ethyl acetate | 84.03 (0.25mg/mL) | Acarbose with inhibition higher than 75% at 0.0125mg/mL | (36)       |
| **Anacardiaceae** |                  |                 |                                        |                                              |            |
| *Mangifera indica* L. | Bark | Ethanol | 84.1 (1mg/mL) | *Phaseolus vulgaris* with 59.4% of inhibition at 0.0125mg/mL | (36)       |
| **Apocynaceae**   |                  |                 |                                        |                                              |            |
| *Holarrhena floribunda* (Don) Durand & Schinz | Leaf | Aqueous buffered | 20-45 (200mg/mL) | Acarbose with inhibition higher than 75% at 200mg/mL | (6)        |
| **Asteraceae**    |                  |                 |                                        |                                              |            |
| *Leontopodium ochroleucum* Beauverd | Aerial part | Methanol | 35.8 (0.3mg/mL) | Acarbose with 79.6% of inhibition at 0.1mg/mL | (32)       |
| *Taraxacum officinale* Web. ex Wigg. | Herb | Aqueous buffered | 20-45 (200mg/mL) | Acarbose with inhibition higher than 75% at 200mg/mL | (6)        |
| *Varthemia iphionoides* Boiss | Aerial part | Aqueous Ethanol | 67.6 (0.2mg/mL) | Non-treated enzyme                                    | (68)       |
| **Balanitaceae**  |                  |                 |                                        |                                              |            |
| *Balanites aegyptiaca* L. | Bark | Aqueous buffered | 45-75 (200mg/mL) | Acarbose with inhibition higher than 75% at 200mg/mL | (6)        |
| **Coniferae**     |                  |                 |                                        |                                              |            |
| *Ginkgo biloba* L. | Leaf | Ethanol | 70 (50mg/mL) | Non-treated enzyme                                    | (69)       |
| Family            | Species                          | Part                  | Extract   | Acarbose inhibition at 0.1mg/mL | Notes                                                                 |
|-------------------|----------------------------------|-----------------------|-----------|---------------------------------|-----------------------------------------------------------------------|
| Crassulaceae      | *Rhodiola rosea* L.              | Rhizome               | Methanol  | 78 (0.3mg/mL)                   | Acarbose with 79.6% of inhibition at 0.1mg/mL                         |
| Ericaceae         | *Vaccinium myrtillus* L.         | Leaf                  | Aqueous buffered | > 75 (200mg/mL)               | Acarbose with inhibition higher than 75% at 200mg/mL                   |
|                   | *Vaccinium uliginosum* L.        | Leaf and wood         | Methanol  | 80.7 (0.3mg/mL)                 | Acarbose with 79.6% of inhibition at 0.1mg/mL                         |
| Euphorbiaceae     | *Phyllanthus amarus* Schum. et Thonn. | Whole plant         | Hexane    | 24.3 (1mg/mL)                   | *Triticum aestivum* with 32% of inhibition at 5 unit/mL               |
|                   | *Phyllanthus maderaspatensis* L. | Whole plant           | Ethanol   | 47.6 (1mg/mL)                   | *Phaseolus vulgaris* with 59.4% of inhibition at 0.0125mg/mL          |
| Geraniaceae       | *Geranium pratense* L.           | Aerial part           | Methanol  | 43.9 (0.3mg/mL)                 | Acarbose with 79.6% of inhibition at 0.1mg/mL                         |
| Grossulariaceae   | *Ribes pulchellum* Turcz.        | Aerial part           | Methanol  | 78.9 (0.3mg/mL)                 | Acarbose with 79.6% of inhibition at 0.1mg/mL                         |
| Lamiaceae         | *Marrubium radiatum* Delile ex Benth. | Aerial part         | Methanol  | 50 (0.0611mg/mL)               | Acarbose with 50% of inhibition at 0.05mg/mL                         |
|                   | *Melissa officinalis* L.         | Leaf                  | Aqueous buffered | 50 (200mg/mL)       | Acarbose with inhibition higher than 75% at 200mg/mL                   |
|                   | *Ocimum tenuiflorum* L.          | Leaf                  | Chloroform | 24.57 (10mg/mL)            | Acarbose with 50% of inhibition at 1.22mg/mL                          |
|                   | *Origanum vulgare* L.            | Leaf                  | Ethanol   | 42 (3.33mg/mL)                 | Non-treated enzyme                                                   |
|                   | *Rosmarinus officinalis* L.      | Leaf                  | Aqueous buffered | 60 (200mg/mL)      | Acarbose with inhibition higher than 75% at 200mg/mL                   |
|                   | *Salvia acetabulosa* L.          | Aerial part           | Methanol  | 50 (0.0912mg/mL)               | Acarbose with 50% of inhibition at 0.05mg/mL                          |
| Fabaceae          | *Cajanus cajan* L.               | Seed                  | Aqueous buffered | 100 (2mg protein)   | Non-treated enzyme                                                   |
|                   | *Galega officinalis* L.          | Herb                  | Aqueous buffered | 35 (200mg/mL)       | Acarbose with inhibition higher than 75% at 200mg/mL                   |
| Plant Family | Species | Part | Type | Concentration | Effect on Acarbose | Reference |
|-------------|---------|------|------|---------------|-------------------|-----------|
| Olneya tesota A.Gray | Seed | Aqueous | 65 (0.0044mg/mL) | Non-treated enzyme | (72) |
| Phaseolus vulgaris L. | Pericarp | Aqueous buffered | 45-75 (200mg/mL) | Acarbose with inhibition higher than 75% at 200mg/mL | (6) |
| Tamarindus indica L. | Leaf | Aqueous buffered | 90 (200mg/mL) | Acarbose with inhibition higher than 75% at 200mg/mL | (6) |
| Malvaceae | Hibiscus sabdariffa Linn. | Flower | Methanol 50% | Non-treated enzyme | (73) |
| Meliaceae | Khaya senegalensis (Desr.) A. Juss. | Bark | Aqueous buffered | Acarbose with inhibition higher than 75% at 200mg/mL | (6) |
| Myrsinaceae | Embelia ribes Burm. f. | Seed | Ethanol | Phaseolus vulgaris with 59.4% of inhibition at 0.0125mg/mL | (36) |
| Myrtaceae | Psidium guajava var. Pomiferum | Leaf | Aqueous | Non-treated enzyme | (29) |
| Psidium guajava L. | Leaf | Ethanol | 31.7 (1.5mg/mL) | Acarbose with 52.1% of inhibition at 1.5mg/mL | (37) |
| Syzygium cumini (L.) Skeels | Leaf | Chloroform | 22.31 (10mg/mL) | Acarbose with 50% of inhibition at 1.22mg/mL | (34) |
| Nyctaginaceae | Bougainvillea spectabilis Wild. | Leaf | Chloroform | Acarbose with 50% of inhibition at 1.22mg/mL | (34) |
| Paeoniaceae | Paeonia anomala L. | Root | Methanol | Acarbose with 79.6% of inhibition at 0.1mg/mL | (32) |
| Pinaceae | Cedrus libani A. Rich | Essential oils from cones | Aqueous buffered | Acarbose with 50% of inhibition at 1.22mg/mL | (33) |
| Polygalaceae | Securidaca longopedunculata Fresen. | Root | Aqueous buffered | Acarbose with inhibition higher than 75% at 200mg/mL | (6) |
| Portulacaceae | | | | | |
Table 2. Natural compounds with α-amylase inhibition

| Compound | Source | Activity | Control | Reference |
|----------|--------|----------|---------|-----------|
| quercetin (3a) | - | 82% of inhibitory activity (50% inhibition at 21.4µM) | Acarbose with 99% of maxim inhibition (50% inhibition at 0.996µM) | (41) |
| 3,7,3’-trimethoxy quercetin (3b) | Varthemia iphionoides Boiss. & Blanche (Asteraceae) | 32% of inhibitory activity (100µM) | Non-treated enzyme | (68) |
| quercetin (3c) | Kalopanax pictum (Araliaceae) | ± 45% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL | (62) |
| rutin (3d) | Sophora japonica L.(Leguminosae) | ± 40% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL | (62) |
| kaempferol (3e) | - | 34% of inhibitory activity (50%) | Acarbose with 99% of maxim inhibition | (41) |
| Compound | Source | Inhibitory Activity | Notes |
|----------|--------|---------------------|-------|
| 5,7,4'-trihydroxy-3-methoxyflavone (3f) | Varthemia iphionoides Boiss. & Blanche (Asteraceae) | 99% of inhibitory activity (100µM) | Non-treated enzyme (68) |
| 5,4'-dihydroxy-3,7-dimethoxyflavone (3g) | Varthemia iphionoides Boiss. & Blanche (Asteraceae) | 98% of inhibitory activity (100µM) | Non-treated enzyme (68) |
| 5, 4'-dihydroxy-3, 6, 7-trimethoxyflavone (3h) | Varthemia iphionoides Boiss. & Blanche (Asteraceae) | 77% of inhibitory activity (100µM) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Astragalin (3i) | Polygala japonica Houtt. (Polygalaceae) | ± 55% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Hyperin (3j) | Kalopanax pictum (Araliaceae) | ± 55% of inhibitory activity (5mg/mL) | Acarbose with 99% of maximal inhibition (50% inhibition at 0.996µM) (41) |
| Isorhamnetin (4a) | Sophora japonica L. (Leguminosae) | ± 70% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Narcisin (4b) | Sophora japonica L. (Leguminosae) | ± 70% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Fisetin (4c) | Sophora japonica L. (Leguminosae) | ± 70% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Myricetin (4d) | Sophora japonica L. (Leguminosae) | ± 70% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Quercetin dimer (5a) | Allium cepa L. (Liliaceae) | 87% of inhibitory activity | Acarbose (76) |
| (4'-O-β-D-glucopyranoside of quercetin dimer) (5b) | Allium cepa L. (Liliaceae) | 56% of inhibitory activity | Acarbose (76) |
| Quercetagetin (6) | Polygala japonica Houtt. (Polygalaceae) | 100% of inhibitory activity | Acarbose with 50% inhibition at 5-50µg/mL (62) |
| Auranetin-5-methylether (8) | Varthemia iphionoides Boiss. & Blanche (Asteraceae) | 18% of inhibitory activity (100µM) | Non-treated enzyme (68) |
| Flavone | Lonicera japonica Thunb. (Caprifoliaceae) | 100% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL (62) |

Notes:
- ± 55% of inhibitory activity (5mg/mL)
- ± 70% of inhibitory activity (5mg/mL)
- 87% of inhibitory activity
- 56% of inhibitory activity
- 100% of inhibitory activity
- 18% of inhibitory activity (100µM)
- 100% of inhibitory activity (5mg/mL)

(50% inhibition at 0.996µM)
| Compound | Source | Inhibitory Activity | Acarbose Effect |
|----------|--------|---------------------|-----------------|
| Luteolin -7-O-glucoside (9b) | Allium cepa L. (Liliaceae) | 88% of inhibitory activity (50% inhibition at 18.4 µM) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Salix gracilistyla Miq. (Salicaceae) | | 82% of inhibitory activity (50% inhibition was not determined) | Acarbose |
| | | 100% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL |
| | | 50% inhibition between 0.2-0.4mM | Acarbose with 50% inhibition at <0.1mM |
| Acacetin (9c) | | 14% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Apigenin (9d) | | 50% inhibition at <0.2mM | Acarbose with 50% inhibition at <0.1mM |
| Lonicerin (9e) | Lonicera japonica Thunb. (Caprifoliaceae) | ± 55% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL |
| Rhoifolin (9f) | Lonicera japonica Thunb. (Caprifoliaceae) | ± 60% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL |
| Diosmetin (10a) | | 19% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Genkwanin (10b) | | 17% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Scutellarein (11a) | | 98% of inhibitory activity (50% inhibition at 9.64 µM) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Eupafolin (11b) | | 99% of inhibitory activity (50% inhibition at 48µM) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Bilobetin (12) | Ginkgo biloba L. (Ginkgoaceae) | ± 25% of inhibitory activity (5mg/mL) | Acarbose with 50% inhibition at 5-50µg/mL |

**Flavonone**

| Compound | Source | Inhibitory Activity | Acarbose Effect |
|----------|--------|---------------------|-----------------|
| Naringenin (13a) | | 26% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Hesperetin (13b) | | 39% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maximum inhibition (50% inhibition at 0.996µM) |
| Compound               | Source                                      | Activity (IC₅₀)                      | Activity (IC₅₀)                      |
|------------------------|---------------------------------------------|-------------------------------------|-------------------------------------|
| hesperidin (13c)       | *Citrus unshiu* (Swingle) Marcow. (Rutaceae) | inhibition was not determined       | inhibition (50% inhibition at 0.996µM) |
| Flavanonol             | *Allium ceca* L. (Liliaceae)                | ± 60% of inhibitory activity (5mg/mL)| Acarbose with 50% inhibition at 5-50µg/mL |
| Alliciocide G (14a)    |                                            | ± 55% of inhibitory activity (5mg/mL)| Acarbose with 50% inhibition at 5-50µg/mL |
| Isoflavone             |                                            | 23% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maxim inhibition (50% inhibition at 0.996µM) |
| daidzein (15a)         |                                            | ± 30% of inhibitory activity (5mg/mL)| Acarbose with 50% inhibition at 5-50µg/mL |
| genistein (15b)        |                                            | 25% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maxim inhibition (50% inhibition at 0.996µM) |
| Proanthocyanidin       |                                            |                                    |                                    |
| catechin (16a)         |                                            | 13% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maxim inhibition (50% inhibition at 0.996µM) |
| catechin hydrate (16a) |                                            | 50% inhibition at > 20 mM           | Acarbose with 50% inhibition at 5.7µM |
| epicatechin (16b)      |                                            | 10% of inhibitory activity (50% inhibition was not determined) | Acarbose with 99% of maxim inhibition (50% inhibition at 0.996µM) |
| (-)-catechin gallato   | *Bergenia ciliate* (Haw) Saxifragaceae     | 50% inhibition at 401 µM            | Non-treated enzyme                  |
| (-)-epicatechin gallato| *Bergenia ciliate* (Haw) Saxifragaceae     | 50% inhibition at 739 µM            | Non-treated enzyme                  |
| epicatechin gallate (16d)|                                    | 50% inhibition at 1.5 mM            | Acarbose with 50% inhibition at 5.7µM |
| epigallocatechin gallate|                                    | 50% inhibition at 1.4 mM            | Acarbose with 50% inhibition at 5.7µM |
| theaflavin (18a)       |                                            | 50% inhibition at 67 µM             | Acarbose 50% inhibition at 5.7µM    |
| theaflavin monogallate |                                    | 50% inhibition at 5.5 µM            | Acarbose 50% inhibition at 5.7µM    |
| theaflavin digallate   |                                    | 50% inhibition at 2.9 µM            | Acarbose 50% inhibition at 5.7µM    |
Others
2-(3,4-Dihydroxybenzoyl)-2,4,6-trihydroxy-3 (2H)-benzofuranone (19)
Aceronidin (20)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Allium cepa L. (Liliaceae) | 88% of inhibitory activity | Acarbose (76) |
| Malpighia emarginata DC. (Malpighiaceae) | 34% of inhibitory activity (50% inhibition at 820µM) | Non-treated enzyme (77) |

Tannin
“Aleppo tannin” (Gallotannin) (21)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| “Gall nut” |                | Dissociation constants of the inhibitor containing complexes EI (K<sub>EI</sub>) 0.82µg mL<sup>-1</sup> vs dissociation constants of the inhibitor containing complexes ESI (K<sub>ESI</sub>) 3.32µg mL<sup>-1</sup> | Differences in dissociation constants (54) |

Pedunculagin (22a)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 14% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

1(α)-O-galloyl pedunculagin (22b)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 56% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

1 (α)-galloyl pedunculagin (22b)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 36% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

strictinin (23a)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 52% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

sanguin H5 (23b)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 56% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

roshenin B (1-desgalloyl sanguin H6 (23c)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 54% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

sanguin H2 (23d)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 36% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |

sanguin H10 (23e)

|                | Plant Family | Inhibitory Activity | Other Information |
|----------------|--------------|----------------------|-------------------|
| Rubus suavissimus S. LEE (Rosaceae) | 23% of inhibitory activity | theaflavin-3,3-di-O-gallate with 83% of inhibition (78) |
| Compound                  | Source                              | Inhibitory Activity (%) | Inhibitory Activity (gallate) |
|--------------------------|-------------------------------------|-------------------------|-------------------------------|
| Sanguin H11 (23f)        | *Rubus suavissimus* S. LEE (Rosaceae) | 1%                      | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Lambertianin A (23g)     | *Rubus suavissimus* S. LEE (Rosaceae) | 36%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Sanguin H6 (23h)         | *Rubus suavissimus* S. LEE (Rosaceae) | 19%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin A (24a)       | *Rubus suavissimus* S. LEE (Rosaceae) | 60%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin B (24b)       | *Rubus suavissimus* S. LEE (Rosaceae) | 60%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin C (24c)       | *Rubus suavissimus* S. LEE (Rosaceae) | 17%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin D (24d)       | *Rubus suavissimus* S. LEE (Rosaceae) | 52%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin E (24e)       | *Rubus suavissimus* S. LEE (Rosaceae) | 14%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Rubusuavin F (24f)       | *Rubus suavissimus* S. LEE (Rosaceae) | 34%                     | theaflavin-3,3'-di-O-gallate with 83% of inhibition (78) |
| Tannic acid (25)         | -                                   | 50% inhibition at < 0.2mM | - (51)                      |
| Cinnamic acid derivatives | chlorogenic acid (26)               | 50% inhibition between 1.4-1.6mM | Acarbose with 50% inhibition at < 0.1mM (6) |
|                         | isochlorogenic acid (27)            | 50% inhibition between 0.6-0.8mM | Acarbose with 50% inhibition at < 0.1mM (6) |
|                         | Rosmarinic acid (28)                | 85% of inhibitory activity | Non-treated enzyme (63)     |
### Terpenes

| Compound                  | Activity            | Source/Specificity                        |
|---------------------------|---------------------|------------------------------------------|
| Squalene (33)             | 30% inhibition      | Non-treated enzyme                       |
| Lupeol (34)               | ±50% inhibition     | α-Amylase inhibitor from wheat seed       |
| 3-O-[(9Z)-9-exadec-9-enoyl]-amyrin (35) | ±50% inhibition | α-Amylase inhibitor from wheat seed       |
| Oleanolic acid (36a)      | ±55% inhibition     | α-Amylase inhibitor from wheat seed       |
| Ursolic acid (36b)        | ±87.5% inhibition   | α-Amylase inhibitor from wheat seed       |
| Mixture of lambertianin C (23i), Sanguin H10 (23e), and Sanguin H6 (23h) | ±75% inhibition | green tea with ±99% of maximum inhibition |
| Mixture of gallic acid (2), proto-catechuic acid (30), caffeic acid (32a), ellagic acid (31), ferulic acid (32b), quercetin (3a) and kaempferol (3e) | 90% inhibition (50% inhibition at 185µg) | α-Amylase inhibitor from wheat seed       |
| Isomeric mixture of oleanolic (36a) and ursolic acid (36b) | ±65% inhibition (50% inhibition at 2.01µg) | α-Amylase inhibitor from wheat seed       |
| Mixture of betulinic acid (37) and 3, 5, 7, 4'-tetrahydroxy flavanone (14b) | 98% inhibition | Not determined                           |

### Isomeric Mixture of Oleanolic (36a) and Ursolic Acid (36b)

| Compound                  | Activity            | Source/Specificity                        |
|---------------------------|---------------------|------------------------------------------|
| Acarbose with 50% inhibition at <0.1mM (6) | 50% inhibition between 1.4-1.6mM | Triticum aestivum                        |
| Acarbose with 50% inhibition at <0.1mM (6) | 50% inhibition between 1.4-1.6mM | Triticum aestivum                        |
| Non-treated enzyme (31) | 57% of inhibitory activity | Spondias mombin L. (Anacardiaceae)       |
| α-Amylase inhibitor from wheat seed (70) | ±55% of inhibitory activity | Rubus idaeus L. variety Glen Ample (Rosaceae) |
| α-Amylase inhibitor from wheat seed (70) | ±75% of inhibitory activity | green tea with ±99% of maximum inhibition |
| α-Amylase inhibitor from wheat seed (70) | 90% of inhibitory activity (50% inhibition at 185µg) | Phyllanthus amarus Schumach. & Thonn. (Euphorbiaceae) |
| α-Amylase inhibitor from wheat seed (70) | ±65% of inhibitory activity (50% inhibition at 2.01µg) | Syzygium cumini L. (Myrtaceae)            |
| Not determined (29) | 98% of inhibitory activity | Not determined                           |
Figure 2. Flavonoids presenting α-amylase inhibition activity
Figure 2. Flavonoids presenting α-amylase inhibition activity (….. Continued)
Figure 2. Flavonoids presenting α-amylase inhibition activity (….. Continued)
Figure 2. Flavonoids presenting α-amylase inhibition activity (….. Continued)
Figure 2. Flavonoids presenting α-amylase inhibition activity (Continued)
Figure 3. Tannins presenting α-amylase inhibition activity

21 gallotannin

22a pedunculagin
22b 1-O-galloyl pedunculagin

23a strictinin

Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued.....)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued.....)
Figure 3. Tannins presenting $\alpha$-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued.....)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued.....)
24b rubusuaviin B

*Figure 3.* Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
24d rubusuaviin D

Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
25 tannic acid

**Figure 3.** Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 3. Tannins presenting α-amylase inhibition activity (Continued…..)
Figure 4. Cinnamic acid derivatives presenting \( \alpha \)-amylase inhibition activity
Figure 5. Terpenes presenting α-amylase inhibition activity
Figure 5. Terpenes presenting α-amylase inhibition activity (Continued…..)